Tests shorter, uneven-dose radiotherapy for lung cancer patients unfit for standard treatment
Tests uneven-dose radiotherapy in adults with advanced lung cancer unfit for standard treatment.
Plain-language title generated from the registry record
Registry title: Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Key facts
- Where
- Aarhus, DenmarkSee the site
Where in Denmark
- Aarhus University HospitalAarhus, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Danish Lung Cancer Group
- Trial code
- NCT03742687
- Record updated
- 11 September 2023
- Original description
The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting seven weeks of intensive treatment.Read full original descriptionShow less
HERAN-Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting seven weeks of intensive treatment.
The aim is to study the efficiency as well as the safety of a new treatment option of heterogeneously hypofractionated radiotherapy for patients with locally advanced NSCLC who are not candidates for standard, high-dose chemoradiotherapy, either due to excessive irradiation of normal tissue (defined as category A patients) or due to fragility of the patient (category B patients).
Inclusion: Histologically or cytological confirmed locally advanced, inoperable NSCLC; Age ≥18 years; Signed informed consent; Performance status 0-2; Able to comply with study and follow-up procedures; Fertile women must have a negative pregnancy test. Fertile men and women must use effective contraception. Fertile women included in the study must use the pill, spiral, depot injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch for the duration of study treatment and one month thereafter.
Exclusion: Prior radiotherapy to the thorax, unless there is no significant overlap of current treatment volumes with previous treatment fields; Uncontrolled metastatic disease; Other active malignant disease; Dose plan conforming to protocol planning criteria not possible.